ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Yumanity Therapeutics Inc

Yumanity Therapeutics Inc (YMTX)

1,89
0,00
(0,00%)
Geschlossen 07 Februar 10:00PM
0,00
0,00
(0,00%)
Nach Börsenschluss: -

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Current Price
1,89
Gebot
1,79
Fragen
1,89
Volumen
-
0,00 Tagesbereich 0,00
0,00 52-Wochen-Bereich 0,00
Marktkapitalisierung
Handelsende
1,89
Handelsbeginn
-
Letzte Trade
Letzter Handelszeitpunkt
Finanzvolumen
-
VWAP
-
Durchschnittliches Volumen (3 Mio.)
-
Ausgegebene Aktien
10.394.000
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-1,39
Gewinn pro Aktie (EPS)
-1,36
Erlöse
5,44M
Nettogewinn
-14,1M

Über Yumanity Therapeutics Inc

Yumanity Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases. The company's lead program, YTX-7739, is in phase 1 clinical development for Parkinson's disease. Yumanity Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases. The company's lead program, YTX-7739, is in phase 1 clinical development for Parkinson's disease.

Sektor
Pharmaceutical Preparations
Branche
Pharmaceutical Preparations
Hauptsitz
Wilmington, Delaware, USA
Gegründet
-

YMTX Neueste Nachrichten

Yumanity Therapeutics Declares Special Dividend In Connection with Proposed Asset Sale to Janssen and Merger with Kineta

Special dividend estimated to be in range of $1.34 to $1.43 per share Payment of special dividend conditioned upon closing of both Asset Sale and Merger, which are subject to stockholder approval...

Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. (“Yumanity” or the “Company”) (Nasdaq: YMTX), a clinical-stage biopharmaceutical company, today announced financial results...

Yumanity Therapeutics Announces Effectiveness of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta, Inc.

BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. (“Yumanity” or the “Company”) (Nasdaq: YMTX) today announced that the registration statement on Form S-4 (the “Registration...

Yumanity Therapeutics Announces Filing of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta

BOSTON, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. (“Yumanity”) (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of...

Yumanity Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Developments

BOSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. (“Yumanity” or the “Company”) (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and...

Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions

Yumanity Therapeutics, Inc. to sell its clinical-stage product candidate YTX-7739 as well as its unpartnered discovery-stage neuroscience product candidates and targets to Janssen Pharmaceutica NV...

Yumanity Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Developments

BOSTON, May 12, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative...

Yumanity Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Developments

BOSTON, March 24, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative...

Yumanity Therapeutics Exploring Strategic Alternatives to Enhance Shareholder Value and Announces Restructuring

BOSTON, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative...

Yumanity Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative...

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

YMTX - Frequently Asked Questions (FAQ)

What is the current Yumanity Therapeutics share price?
The current share price of Yumanity Therapeutics is US$ 1,89
How many Yumanity Therapeutics shares are in issue?
Yumanity Therapeutics has 10.394.000 shares in issue
What is the market cap of Yumanity Therapeutics?
The market capitalisation of Yumanity Therapeutics is USD 19,64M
What is the 1 year trading range for Yumanity Therapeutics share price?
Yumanity Therapeutics has traded in the range of US$ 0,00 to US$ 0,00 during the past year
What is the PE ratio of Yumanity Therapeutics?
The price to earnings ratio of Yumanity Therapeutics is -1,39
What is the cash to sales ratio of Yumanity Therapeutics?
The cash to sales ratio of Yumanity Therapeutics is 3,61
What is the reporting currency for Yumanity Therapeutics?
Yumanity Therapeutics reports financial results in USD
What is the latest annual turnover for Yumanity Therapeutics?
The latest annual turnover of Yumanity Therapeutics is USD 5,44M
What is the latest annual profit for Yumanity Therapeutics?
The latest annual profit of Yumanity Therapeutics is USD -14,1M
What is the registered address of Yumanity Therapeutics?
The registered address for Yumanity Therapeutics is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the Yumanity Therapeutics website address?
The website address for Yumanity Therapeutics is www.kinetabio.com
Which industry sector does Yumanity Therapeutics operate in?
Yumanity Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
LTRYLottery com Inc
US$ 1,41
(187,81%)
272,77M
APPSDigital Turbine Inc
US$ 4,98
(96,06%)
121,53M
LIPOLipella Pharmaceuticals Inc
US$ 4,65
(80,23%)
86,93M
SGBXSafe and Green Holdings Corporation
US$ 1,16
(75,20%)
33,51M
QNTMQuantum Biopharma Ltd
US$ 14,425
(68,12%)
35,68M
TOIIWOncology Institute Inc
US$ 0,020771
(-46,05%)
208
BTAIBioXcel Therapeutics Inc
US$ 0,1852
(-38,04%)
9,81M
SDASunCar Technology Group Inc
US$ 5,40
(-36,02%)
5,11M
CRMLCritical Metals Corporation
US$ 5,75
(-34,06%)
946,34k
SRTSSensus Healthcare Inc
US$ 6,07
(-32,48%)
2,89M
MGOLMGO Global Inc
US$ 0,1801
(29,57%)
391,75M
LTRYLottery com Inc
US$ 1,41
(187,81%)
272,77M
NVDANVIDIA Corporation
US$ 128,68
(3,08%)
251,47M
CYNCYNGN Inc
US$ 0,081404
(-0,73%)
184,48M
RIMEAlgorhythm Holdings Inc
US$ 0,0211
(0,96%)
135M
Keine Diskussionen Gefunden.
Neuen Thread Erstellen